DTX-104

DTX-104 is a preclinical-stage bispecific antibody being developed by Dual Therapeutics (also known as Dualitas Therapeutics) for the treatment of allergic diseases. As a bispecific antibody, it is engineered to simultaneously target two different mediators or receptors within the allergic signaling pathway, potentially offering a more robust therapeutic effect than conventional monoclonal antibodies. The specific molecular targets for DTX-104 have not been publicly disclosed by the developer, but the program represents the company's expansion of its Dual-Action platform into the immunology and allergy space. The drug is currently in the lead generation and optimization phase of preclinical development.